Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0LXSXV |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | B62-H3L3 |
|||||
| Organization | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO. LTD. | SANYOU BIOPHARMACEUTICALS CO. LTD. |
|||||
| Synonyms |
B62-H3L3
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEYVATINSNGGNTYY
ADSVKGRFTISRDNSKNTLYLQMGSLRAEDTAMYYCARDSLGLRRRDYAMDYWGQGTTVT VSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEL LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPS RDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYVMSWVRQAPGKGLEYVATINSNGGNTYY
ADSVKGRFTISRDNSKNTLYLQMGSLRAEDTAMYYCARDSLGLRRRDYAMDYWGQGTTVT VSS Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GFTFSSYVMS
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
TINSNGGNTY
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
DSLGLRRRDYAMDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTQSPSSLSASVGDRVTITCVTSIDIDDDVNWYQQKPGKAPKLLISAGNTLRPGVPS
RFSGSGSGTDFTFTISSLQPEDIATYYCLQSDNLPYTFGGGTKLEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIQMTQSPSSLSASVGDRVTITCVTSIDIDDDVNWYQQKPGKAPKLLISAGNTLRPGVPS
RFSGSGSGTDFTFTISSLQPEDIATYYCLQSDNLPYTFGGGTKLEIK Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
VTSIDIDDDVN
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
AGNTLRP
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
LQSDNLPYT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
B62-H3L3-MMAE [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
33.54%
|
|||
| Method Description |
Cell line-derived xenograft models were established in nude mice by subcutaneous injection of 1x106 (HT-29) tumor cells, and treatment with 2mg/kg B62-H3L3-MMAE (BIWƨ) was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
36.38%
|
|||
| Method Description |
Cell line-derived xenograft models were established in female nude mice (Balb/C),by subcutaneous injection of 1x106 (A549) tumor cells,and treatment with 10mpk (mg/kg)B62-H3L3-MMAE (BIWƧ)was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 48.
|
||||
| In Vivo Model | A549 xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
73.87%
|
|||
| Method Description |
Cell line-derived xenograft models were established in nude mice by subcutaneous injection of 1x106 (HT-29) tumor cells, and treatment with 10mg/kg B62-H3L3-MMAE (BIWƨ) was initiated after tumor volume about 100mm3. Determined tumor volume after the experiment, measured at day 51.
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
28.64 nM
|
High ROR1 expression (ROR1 +++) | ||
| Method Description |
MDA-MB-468 cell line was plated at 2×105cell/mL, 90uL/well,12 hours later, ADCs (500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, 0.05nM) were added and incubated for 72h,then 10uL CCK8 (Bimake,B34304)was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
50.14 nM
|
|||
| Method Description |
Jeko-1 cell line was plated at 1×105cell/mL, 90uL/well,12 hours later, ADCs (500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, 0.05nM) were added and incubated for 72h,then 10uL CCK8 (Bimake,B34304)was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
121.6 nM
|
|||
| Method Description |
HT-29 cell line (1×104cell/mL,100uL/well) , the ADCs (2000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 1.953nM) were added 12 hours later, and incubated for 96h, then 40uL/well MTS (Promega,G3580) was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Colon adenocarcinoma | HT-29 cells | CVCL_0320 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
128.6 nM
|
|||
| Method Description |
NCI-H1944 cell line was plated at 1.2×105cell/mL, 90uL/well,12 hours later, ADCs (500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, 0.05nM) were added and incubated for 72h,then 10uL CCK8 (Bimake,B34304)was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1944 cells | CVCL_1508 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
311.4 nM
|
Moderate ROR1 expression (ROR1++) | ||
| Method Description |
A549 cell line at 1×104cell/mL,100uL/well, 12 hours later,ADCs (2000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 1.953nM) were added and incubated for 72h, then 40uL/well MTS (Promega,G3580) was added to each well and a microplate reader was used for detection OD492.
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
CO20240013452A2 ADC1 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
33.54%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously withHT-29 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (2 mg/kg) (BIWƨ).
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
36.38%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously with A549 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) (BIWƧ).
|
||||
| In Vivo Model | A549 xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
73.87%
|
Positive ROR1 expression (ROR1+++/++) | ||
| Method Description |
Female Balb/C nude mice between 6-8 weeks of age were injected subcutaneously withHT-29 cells, when tumors reached appproximately 100 mm^3, animals were matched by tumor volume into treatment or controls groups. The test articles were given by tail vein at a dose (10 mg/kg) (BIWƨ).
|
||||
| In Vivo Model | HT-29 xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
28.64 nM
|
|||
| Method Description |
ADCs were tested in MDA-MB-468 cells, and were added at final working concentration at 500 nM, 158 nM, 50 nM, 15.8 nM, 5 nM, 1.58 nM, 0.5 nM, 0.158 nM, 0.05 Nm, incubated for 3 days.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
50.14 nM
|
|||
| Method Description |
ADCs were tested in Jeko-1 cells, and were added at final working concentration at 500 nM, 158 nM, 50 nM, 15.8 nM, 5 nM, 1.58 nM, 0.5 nM, 0.158 nM, 0.05 Nm, incubated for 3 days.
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
121.6 nM
|
|||
| Method Description |
ADCs were tested in HT-29 cells, and were added at final working concentration at 2000 nM, 500 nM, 250 nM, 125 nM, 62.5 nM, 31.25 nM, 15.625 nM, 7.813 nM, 1.953 nM, incubated for 4 days.
|
||||
| In Vitro Model | Colon adenocarcinoma | HT-29 cells | CVCL_0320 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
128.6 nM
|
|||
| Method Description |
ADCs were tested in NCI-H1944 cells, and were added at final working concentration at 500 nM, 158 nM, 50 nM, 15.8 nM, 5 nM, 1.58 nM, 0.5 nM, 0.158 nM, 0.05 Nm, incubated for 3 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1944 cells | CVCL_1508 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
311.4 nM
|
|||
| Method Description |
ADCs were tested in A549 cells, and were added at final working concentration at 2000 nM, 500 nM, 250 nM, 125 nM, 62.5 nM, 31.25 nM, 15.625 nM, 7.813 nM, 1.953 nM, incubated for 3 days.
|
||||
| In Vitro Model | Lung adenocarcinoma | A549 cells | CVCL_0023 | ||
kR1020250008730A ADC1 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
33.54%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by unilateral subcutaneous injection of 1×10^6 HT-29 cells into female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, B62-H3L3-MMAE was administered at a dose of 2 mg/kg. The treatment was given twice a week for 4 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | HT-29-xenograft model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
36.38%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by unilateral subcutaneous injection of 1×10^6 A549 cells into female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, B62-H3L3-MMAE was administered at a dose of 10 mg/kg. The treatment was given twice a week for 3 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | A549-xenograft model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
73.87%
|
|||
| Method Description |
A xenograft model derived from cell lines was established by unilateral subcutaneous injection of 1×10^6 HT-29 cells into female Balb/C nude mice. When the tumor volume reached approximately 100 mm^3, B62-H3L3-MMAE was administered at a dose of 10 mg/kg. The treatment was given twice a week for 4 weeks. The tumor inhibition rate was calculated at the end of the experiment.
Click to Show/Hide
|
||||
| In Vivo Model | HT-29-xenograft model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC52) |
128.6 nM
|
|||
| Method Description |
NCI-H1944 cells were added with ADC samples, and the drug concentration gradient was diluted to 500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, and 0.05 nM. The cells were cultured at 37°C with 5% CO2 for 72 hours. Then, 10 uL of LCK8 (Bimake, B34304) was added to each well, and the cells were incubated at 37°C for 1 hour. The data were read at OD450 using a microplate reader.
Click to Show/Hide
|
||||
| In Vitro Model | Lung adenocarcinoma | NCI-H1944 cells | CVCL_1508 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC51) |
28.64 nM
|
|||
| Method Description |
MDA-MB-468 cells were added with ADC samples, and the drug concentration gradient was diluted to 500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, and 0.05 nM. The cells were cultured at 37°C with 5% CO2 for 72 hours. Then, 10 uL of LCK8 (Bimake, B34304) was added to each well, and the cells were incubated at 37°C for 1 hour. The data were read at OD450 using a microplate reader.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-468 cells | CVCL_0419 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
50.14 nM
|
|||
| Method Description |
Jeko-1 cells were co-cultured with ADC samples, and the drug concentration gradient was diluted to 500, 158, 50, 15.8, 5, 1.58, 0.5, 0.158, and 0.05 nM. The cells were cultured at 37°C with 5% CO2 for 72 hours. Then, 10 uL of LCK8 (Bimake, B34304) was added to each well, and the reaction was incubated at 37°C for 1 hour. The data were read at OD450 using a microplate reader.
Click to Show/Hide
|
||||
| In Vitro Model | Mantle cell lymphoma | JeKo-1 cells | CVCL_1865 | ||
References